Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Dalbavancin

FDA approved · Rx

Lipoglycopeptide antibiotic

Also known as: Dalvance, Dalbavancin Hydrochloride, BI397, dalbavancine, Dalbavancina, VER001, BI 397, MDL 63,397, MDL 64,397

Evidence score

91/ 100

Strong evidence

Strong, human-grade evidence

Regulatory standing. FDA-approved prescription medicine
Human trials. Backed by controlled human studies
Registered human trials. 39 registered studies on ClinicalTrials.gov, most advanced Phase 4
2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Dalbavancin, sold as Dalvance, is a semisynthetic lipoglycopeptide antibiotic related to the glycopeptide class that includes vancomycin. It is thought to act by binding to building blocks of the bacterial cell wall, blocking cell wall construction in Gram-positive bacteria such as Staphylococcus aureus, including methicillin-resistant strains. Its long half-life means it stays in the body much longer than many other antibiotics.

What the evidence shows

Automatic summaryHuman trials

Dalbavancin is FDA approved for acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, supported by 38 registered human trials reaching Phase 4 and over 1,000 published papers. Its use for other infections, such as bone or heart valve infections, has been studied but is not an approved indication.